The crosstalk between c-Met and TGF-β signaling holds particular significance for comprehending the multifaceted effects of crizotinib in cancer treatment, particularly in tumors exhibiting dysregulation of both pathways (Figure 2). Here, TGFB1 is linked to cancer.